Socium Therapeutics

Socium Therapeutics is a biotechnology company developing a novel class of "Sociable" cell therapies designed to treat solid tumors. The company's platform technology engineers T cells to serve as local factories that produce and secrete therapeutic proteins, such as cytokines, specifically within the tumor microenvironment. This localized delivery is intended to activate the broader immune system against the cancer while avoiding the systemic side effects typically associated with such potent biologics. By combining the targeting precision of cell therapy with the localized production of therapeutic payloads, Socium aims to provide more effective treatments for patients with refractory solid malignancies. The company is backed by prominent investors including 5AM Ventures and Canaan Partners and is currently in the pre-clinical stage of development.